Oncology Emergency Essentials: Addressing Tumor Lysis Syndrome in Your Practice

Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Oncology Emergency Essentials: Addressing Tumor Lysis Syndrome in Your Practice

Oncology Emergency Essentials: Addressing Tumor Lysis Syndrome in Your Practice
Dr. Mitchell Cairo discusses TLS while focusing on a comprehensive TLS risk classification system

Available credits: 0.50


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The goal of this program is to increase the knowledge and understanding of healthcare providers involved in the care of cancer patients at risk for tumor lysis syndrome (TLS). This interview with renowned expert, Dr. Mitchell Cairo, will focus on a comprehensive TLS risk classification system developed by an international TLS expert consensus panel.

    TLS is a potentially serious and life-threatening consequence of the successful treatment of various malignancies resulting from massive tumor cell lysis. The best way to manage this condition is through prevention, however the risk for TLS is often underestimated by many clinicians. TLS usually occurs in rapidly proliferating hematologic cancers, however with new advances seen in cancer treatment on a regular basis, the incidence of TLS may increase and may also arise in a broader spectrum of malignancies. As a result, clinicians will likely see an increased number of cancer patients presenting with TLS in their practice. This oncologic emergency requires immediate intervention. As TLS is potentially fatal if not recognized and promptly treated, it is essential to identify patients at risk. Prevention of TLS depends on heightened awareness, accurate assessment of risk factors, and risk-based management.

    This expert interview is accompanied by a downloadable clinical tool, including a TLS risk stratification algorithm, as well as prophylaxis and management recommendations.

  • Learning Objectives

    Upon completion of this educational program, participants will be able to:

    1. Recognize factors that may place patients at risk for TLS, including type of malignancy and new and emerging cancer therapies
    2. Identify patients at risk for TLS who would benefit from close monitoring and prophylactic measures
    3. Apply appropriate preventative and treatment strategies for hyperuricemia and TLS in cancer patients
  • Target Audience

    Hematologists, Oncologists, Nephrologists, Cardiologists, Emergency Medicine Physicians, Internal Medicine Specialists, Oncology Nurses, Oncology Nurse Practitioners, and Oncology Physician Assistants

  • Disclosure of Conflicts of Interest

    Mitchell S. Cairo, MD
    Chief, Pediatric Hematology, Oncology and Stem Cell Transplantation
    Director, Children and Adolescent Cancer and Blood Disease Center
    Medical and Scientific Director, WMC Cellular and Tissue Engineering Laboratory
    Medical Director, WMC Hematotherapy Program
    Co-Chair, WMC Cancer Committee 
    Associate Chairman, Department of Pediatrics
    Professor of Pediatrics, Medicine, Pathology, Microbiology & Immunology, Cell Biology & Anatomy, and Public Health
    Maria Fareri Children’s Hospital at Westchester Medical Center (WMC)
    New York Medical College

    Dr. Mitchell S. Cairo is has disclosed the following relevant financial relationships: Consultant for Sanofi US

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    • Andrea Funk has nothing to disclose
    • Lynn Heywood-McLean has nothing to disclose
    • Athena Kalyvas has nothing to disclose
    • Sarah Scheigetz has nothing to disclose
  • Accreditation and Credit Designation Statements

    Clinical and Patient Educators Association designate this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and CME Solutions. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

    CPEA Contact Information
    For information about the accreditation of this program, please contact CPEA at 303-953-4580 or

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an independent educational grant from Sanofi US

  • Terms of Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither Clinical & Patient Educators Association nor CME Solutions International recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Clinical & Patient Educators Association and CME Solutions International. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Instructions to Receive Credit

    There are no fees for participating in and receiving CME credit for this activity. During the period of October 27, 2017, through October 27, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) listen to the full content of the activity and reflect upon its teachings; 3) successfully complete the post-test with a passing score and the evaluation at the end of the activity.

    Participants who successfully complete the activity, post test and evaluation will have a statement of credit made available immediately.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Clinical & Patient Educators Association & CME Solutions International. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of ReachMD you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.